Drug Shortage Report for LOXAPAC IM
| Report ID | 226623 |
| Drug Identification Number | 02169991 |
| Brand name | LOXAPAC IM |
| Common or Proper name | LOXAPAC IM |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | LOXAPINE |
| Strength(s) | 50MG |
| Dosage form(s) | SOLUTION LIQUID |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 1ML |
| ATC code | N05AH |
| ATC description | ANTIPSYCHOTICS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-07-01 |
| Actual start date | |
| Estimated end date | 2024-09-27 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2024-04-30 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2024-04-30 | French | Compare |
| v2 | 2024-04-30 | English | Compare |
| v1 | 2024-04-30 | English | Compare |
Showing 1 to 3 of 3